Rolston K V, LeBlanc B, Ho D H
J Antimicrob Chemother. 1986 Feb;17(2):161-3. doi: 10.1093/jac/17.2.161.
The activity of a novel macrolide, RU 28965, was compared to that of erythromycin against Gram-positive organisms isolated mainly from cancer patients. RU 28965 was active against streptococci including Streptococcus pneumoniae and streptococcal groups A, B and G. It was also active against methicillin-susceptible staphylococci, Bacillus cereus and Listeria monocytogenes. Its activity against these organisms was generally equal to that of erythromycin. RU 28965 was moderately active against enterococci and inactive against JK diphtheroids and three different species of coagulase-negative staphylococci. Organisms resistant to erythromycin were also resistant to RU 28965.
将一种新型大环内酯类药物RU 28965与红霉素针对主要从癌症患者中分离出的革兰氏阳性菌的活性进行了比较。RU 28965对包括肺炎链球菌以及A、B和G组链球菌在内的链球菌具有活性。它对甲氧西林敏感葡萄球菌、蜡样芽孢杆菌和单核细胞增生李斯特菌也有活性。其对这些细菌的活性总体上与红霉素相当。RU 28965对肠球菌有中度活性，对JK类白喉杆菌和三种不同的凝固酶阴性葡萄球菌无活性。对红霉素耐药的细菌对RU 28965也耐药。
